WATCHMAN FLX™ CT Study

NCT ID: NCT05324371

Last Updated: 2025-07-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-09
• Study Completion Date: 2025-01-23

Brief Summary

WATCHMAN FLX™ CT is a prospective, single-arm, single-center, post-market investigation to assess device tissue coverage in subjects with non-valvular atrial fibrillation (AF) who receive the WATCHMAN FLX device to reduce the risk of stroke. Serial advanced imaging modalities such as CT and TEE will be used.

Conditions

The Focus of the Study is to Reduce the Risk of Stroke and Life-threatening Bleeding Events in Patients With Non-valvular Atrial Fibrillation

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Device Arm

WATCHMAN FLX™ device implantation

Group Type: EXPERIMENTAL

Watchman FLX Device

Intervention Type: DEVICE

Left atrial appendage closure using the Watchman FLX device

Interventions

Watchman FLX Device

Left atrial appendage closure using the Watchman FLX device

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Subject is of legal age to participate in the study per the laws of their respective geography.
• Subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve).
• Subject is clinically indicated for a WATCHMAN FLX device.
• Subject is deemed suitable for the protocol-defined pharmacologic regimen.
• Subject or legal representative is able to understand and willing to provide written informed consent to participate in the study.
• Subject is able and willing to return for required follow-up visits and examinations.

Exclusion Criteria

• Subject is currently enrolled in another investigational study, except if the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatment.
• Subject has eGFR <30 mL/min (chronic kidney disease stage IV or stage V).
• Subject is contraindicated for TEE.
• Subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction (e.g., due to an underlying hypercoagulable state).
• Subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to, cardioversion, percutaneous coronary intervention, cardiac ablation, cataract surgery, etc.).
• Subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment.
• Subject had a prior major bleeding event per ISTH definitions within the 30 days prior to enrollment. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source are a further exclusion regardless of timing of the bleeding event.
• Subject has an active bleed.
• Subject has a reversible cause for AF or has transient AF.
• Subject has no LAA or the LAA is surgically ligated.
• Subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment.
• Subject has a history of atrial septal repair or has an atrial septal defect/patent foramen ovale (ASD/PFO) device.
• Subject has a known contraindication to percutaneous catheterization procedure.
• Subject has a cardiac tumor.
• Subject has signs/symptoms of acute or chronic pericarditis.
• Subject has an active infection.
• There is evidence of tamponade physiology.
• Subject has New York Heart Association Class IV congestive heart failure at the time of enrollment.
• Subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment per study physician's discretion).
• Subject has a documented life expectancy of less than 6 months.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boston Scientific Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jens Erik Nielsen-Kudsk, MD

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital Skejby

Locations

Aarhus University Hospital

Aarhus, , Denmark

Countries

Denmark

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

S2423

Identifier Type: -

Identifier Source: org_study_id